These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

274 related articles for article (PubMed ID: 31476157)

  • 1. Developing Effective Alzheimer's Disease Therapies: Clinical Experience and Future Directions.
    Elmaleh DR; Farlow MR; Conti PS; Tompkins RG; Kundakovic L; Tanzi RE
    J Alzheimers Dis; 2019; 71(3):715-732. PubMed ID: 31476157
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
    Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
    Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beyond immunotherapy: new approaches for disease modifying treatments for early Alzheimer's disease.
    Ruthirakuhan M; Herrmann N; Suridjan I; Abraham EH; Farber I; Lanctôt KL
    Expert Opin Pharmacother; 2016 Dec; 17(18):2417-2429. PubMed ID: 27825018
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current Landscape of Late-Phase Clinical Trials for Alzheimer's Disease: Comparing Regional Variation Between Subjects in Japan and North America.
    Kikuchi M; Adachi N; Matsumaru N; Tsukamoto K
    Pharmaceut Med; 2019 Dec; 33(6):511-518. PubMed ID: 31933241
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Statistically-Derived Composite Measures for Assessing the Efficacy of Disease-Modifying Therapies in Prodromal Alzheimer's Disease Trials: An AIBL Study.
    Burnham SC; Raghavan N; Wilson W; Baker D; Ropacki MT; Novak G; Ames D; Ellis K; Martins RN; Maruff P; Masters CL; Romano G; Rowe CC; Savage G; Macaulay SL; Narayan VA; ;
    J Alzheimers Dis; 2015; 46(4):1079-89. PubMed ID: 26402634
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Detecting Treatment Group Differences in Alzheimer's Disease Clinical Trials: A Comparison of Alzheimer's Disease Assessment Scale - Cognitive Subscale (ADAS-Cog) and the Clinical Dementia Rating - Sum of Boxes (CDR-SB).
    Wessels AM; Dowsett SA; Sims JR
    J Prev Alzheimers Dis; 2018; 5(1):15-20. PubMed ID: 29405227
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FUNDAMANT: an interventional 72-week phase 1 follow-up study of AADvac1, an active immunotherapy against tau protein pathology in Alzheimer's disease.
    Novak P; Schmidt R; Kontsekova E; Kovacech B; Smolek T; Katina S; Fialova L; Prcina M; Parrak V; Dal-Bianco P; Brunner M; Staffen W; Rainer M; Ondrus M; Ropele S; Smisek M; Sivak R; Zilka N; Winblad B; Novak M
    Alzheimers Res Ther; 2018 Oct; 10(1):108. PubMed ID: 30355322
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How many patients are eligible for disease-modifying treatment in Alzheimer's disease? A French national observational study over 5 years.
    Epelbaum S; Paquet C; Hugon J; Dumurgier J; Wallon D; Hannequin D; Jonveaux T; Besozzi A; Pouponneau S; Hommet C; Blanc F; Berly L; Julian A; Paccalin M; Pasquier F; Bellet J; Boutoleau-Bretonniere C; Charriau T; Rouaud O; Madec O; Mouton A; David R; Bekadar S; Fabre R; Liegey E; Deberdt W; Robert P; Dubois B
    BMJ Open; 2019 Jun; 9(6):e029663. PubMed ID: 31239309
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer's disease drug development pipeline: 2022.
    Cummings J; Lee G; Nahed P; Kambar MEZN; Zhong K; Fonseca J; Taghva K
    Alzheimers Dement (N Y); 2022; 8(1):e12295. PubMed ID: 35516416
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacotherapies for sleep disturbances in Alzheimer's disease.
    McCleery J; Cohen DA; Sharpley AL
    Cochrane Database Syst Rev; 2014 Mar; (3):CD009178. PubMed ID: 24659320
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Vascular biomarkers to predict response to exercise in Alzheimer's disease: the study protocol.
    Li D; Thomas R; Tsai MY; Li L; Vock DM; Greimel S; Yu F
    BMJ Open; 2016 Dec; 6(12):e011054. PubMed ID: 28039287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bapineuzumab for mild to moderate Alzheimer's disease in two global, randomized, phase 3 trials.
    Vandenberghe R; Rinne JO; Boada M; Katayama S; Scheltens P; Vellas B; Tuchman M; Gass A; Fiebach JB; Hill D; Lobello K; Li D; McRae T; Lucas P; Evans I; Booth K; Luscan G; Wyman BT; Hua L; Yang L; Brashear HR; Black RS;
    Alzheimers Res Ther; 2016 May; 8(1):18. PubMed ID: 27176461
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Predicting and Tracking Short Term Disease Progression in Amnestic Mild Cognitive Impairment Patients with Prodromal Alzheimer's Disease: Structural Brain Biomarkers.
    Marizzoni M; Ferrari C; Jovicich J; Albani D; Babiloni C; Cavaliere L; Didic M; Forloni G; Galluzzi S; Hoffmann KT; Molinuevo JL; Nobili F; Parnetti L; Payoux P; Ribaldi F; Rossini PM; Schönknecht P; Salvatore M; Soricelli A; Hensch T; Tsolaki M; Visser PJ; Wiltfang J; Richardson JC; Bordet R; Blin O; Frisoni GB;
    J Alzheimers Dis; 2019; 69(1):3-14. PubMed ID: 29914031
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heterogeneity of neuroanatomical patterns in prodromal Alzheimer's disease: links to cognition, progression and biomarkers.
    Dong A; Toledo JB; Honnorat N; Doshi J; Varol E; Sotiras A; Wolk D; Trojanowski JQ; Davatzikos C;
    Brain; 2017 Mar; 140(3):735-747. PubMed ID: 28003242
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Safety, efficacy, and biomarker findings of PBT2 in targeting Abeta as a modifying therapy for Alzheimer's disease: a phase IIa, double-blind, randomised, placebo-controlled trial.
    Lannfelt L; Blennow K; Zetterberg H; Batsman S; Ames D; Harrison J; Masters CL; Targum S; Bush AI; Murdoch R; Wilson J; Ritchie CW;
    Lancet Neurol; 2008 Sep; 7(9):779-86. PubMed ID: 18672400
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Poor Safety and Tolerability Hamper Reaching a Potentially Therapeutic Dose in the Use of Thalidomide for Alzheimer's Disease: Results from a Double-Blind, Placebo-Controlled Trial.
    Decourt B; Drumm-Gurnee D; Wilson J; Jacobson S; Belden C; Sirrel S; Ahmadi M; Shill H; Powell J; Walker A; Gonzales A; Macias M; Sabbagh MN
    Curr Alzheimer Res; 2017; 14(4):403-411. PubMed ID: 28124585
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.
    Weiner MW; Veitch DP; Aisen PS; Beckett LA; Cairns NJ; Cedarbaum J; Green RC; Harvey D; Jack CR; Jagust W; Luthman J; Morris JC; Petersen RC; Saykin AJ; Shaw L; Shen L; Schwarz A; Toga AW; Trojanowski JQ;
    Alzheimers Dement; 2015 Jun; 11(6):e1-120. PubMed ID: 26073027
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future.
    Cummings J; Ritter A; Zhong K
    J Alzheimers Dis; 2018; 64(s1):S3-S22. PubMed ID: 29562511
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Drugs in Clinical Trials for Alzheimer's Disease: The Major Trends.
    Bachurin SO; Bovina EV; Ustyugov AA
    Med Res Rev; 2017 Sep; 37(5):1186-1225. PubMed ID: 28084618
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 14.